Hyperion Therapeutics, Inc.
2000 Sierra Point Parkway, Suite 400
Brisbane, CA 94005
May 7, 2015
VIA EDGAR
Daniel F. Duchovny
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
| RE: | Hyperion Therapeutics, Inc. |
Registration Statement on Form S-3 (File No. 333-190624)
Filed August 14, 2013
Application for Withdrawal
Dear Mr. Duchovny:
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Act”), Hyperion Therapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal, effective as of the date hereof or at the earliest possible practicable date hereafter, of its Registration Statement on Form S-3 (Registration No. 333-190624), together with all exhibits thereto (collectively, the “Registration Statement”). The Registration Statement was originally filed with the Commission on August 14, 2013. The Registration Statement was declared effective on September 13, 2013.
As a result of the successful completion of the merger of the Company and Ghrian Acquisition Inc., a subsidiary of Horizon Pharma, Inc. and a Delaware corporation, the Company has determined that it is in its best interest to withdraw the Registration Statement at this time. The Company confirms that no securities have been sold pursuant to the Registration Statement.
If you have any questions or comments or require further information, please do not hesitate to email Paul W. Hoelscher, the Company’s Chief Financial Officer and Secretary at orPHoelscher@horizonpharma.com. Thank you for your assistance in this matter.
| Very truly yours, | ||
| Hyperion Therapeutics, Inc. | ||
| By: | /s/ Paul W. Hoelscher | |
| Name: | Paul W. Hoelscher | |
| Title: | Chief Financial Officer and Secretary | |
